Cyclopharm (ASX:CYC) has announced it has entered into an interim agreement to supply the Veterans Health Administration, the most extensive integrated government healthcare system in the US, with the pharmaceutical and consumable components of Technegas.

Monash University researchers are assessing a new drug that researchers believe could have an impact on a form of dementia.

The Australian Medtech Manufacturing Alliance has been established with the goal of growing opportunities for medtech manufacturers to sell to health services.

Life sciences financier Endpoints Capital has advanced pioneering Australian firm Vaxxas $9.7 million for its Research and Development Tax Incentive.

Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.

CEO Professor Alan Trounson AO said, “The successful capital raising, in times of scant investment support in biotechnology, is welcome and further supports confidence in the company for the delivery of effective therapies in ovarian cancer and other difficult diseases.”

Australian medical technology company Artrya (ASX:AYA) has submitted its application for regulatory approval for the Salix Coronary Anatomy product to the US FDA.

AusBiotech has always been for its members. Built by our members, to be the national voice of our sector we are proud to support our member's growth and leverage our national convening power to shape policy, foster knowledge sharing, and collaborate to advance life sciences in our country. Together, we work to help our members thrive. 

Cell therapy company Mesoblast (ASX:MSB) has entered into a convertible note subscription agreement with its largest shareholder, Gregory George, to issue up to US$50 million convertible notes at its discretion.

PolyNovo chairman David Williams said, "After 14 years Bruce has selflessly decided to stand aside to make way for new blood and concentrate on his other Board roles. He will be missed but I am confident he will still be available for his sage advice."

Percheron Therapeutics (ASX:PER) has announced the completion of a nine-month toxicology study in non-human primates for its lead program, avicursen.

Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced a partnership with US-based Achieve that aims to improve patient access to autologous cell therapies.

AusBiotech’s biotech and medtech members are being invited to complete the organisation’s first annual AusBiotech Voice on Investment Survey.

Opyl (ASX:OPL) has announced a new agreement with clinical research organisation and strategic planning and commercialisation advisory firm Biointelect.

Lumos Diagnostics (ASX:LDX) has been awarded placement of their novel point-of-care test, FebriDx, on the MediGroup national contract, making it available to all their members in the United States.

Argenica Therapeutics (ASX:AGN) has announced the completion of crucial safety studies that are required to be included in its IND application.

New research findings reveal that people who inherit a genetic biomarker known to predict poorer outcomes with routine prostate cancer treatment could be successfully treated and have better survival outcomes with personalised hormonal therapy.